These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 25065536

  • 1. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH.
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
    Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.
    J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [Abstract] [Full Text] [Related]

  • 6. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB, Perry CM.
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [Abstract] [Full Text] [Related]

  • 7. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
    Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ.
    Thromb Haemost; 2013 Oct; 110(4):732-41. PubMed ID: 23846019
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
    Gourzoulidis G, Kourlaba G, Kakisis J, Matsagkas M, Giannakoulas G, Gourgoulianis KI, Vassilakopoulos T, Maniadakis N.
    Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
    [Abstract] [Full Text] [Related]

  • 15. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT, Dobromirski M.
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.
    J Med Econ; 2011 Jun; 14(6):824-34. PubMed ID: 22023098
    [Abstract] [Full Text] [Related]

  • 18. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA, Ogden K, Mody SH, Bookhart B.
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [Abstract] [Full Text] [Related]

  • 19. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT, Wells PS, Beyer-Westendorf J, Prandoni P, Bounameaux H, Kubitza D, Schneider J, Pisters R, Fedacko J, Fontes-Carvalho R, Lensing AW.
    Thromb Haemost; 2016 Sep 27; 116(4):739-46. PubMed ID: 27535349
    [Abstract] [Full Text] [Related]

  • 20. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A.
    N Engl J Med; 2012 Apr 05; 366(14):1287-97. PubMed ID: 22449293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.